Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress Mar 01, 2021 4:05pm EST
Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021 Feb 18, 2021 4:01pm EST
Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Feb 08, 2021 9:00am EST
Atara Biotherapeutics to Present Data at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience Jan 19, 2021 4:14pm EST
Atara Biotherapeutics Will Present Recent Advancements and Key Upcoming Milestones at the 39th Annual J.P. Morgan Healthcare Conference Jan 10, 2021 4:06pm EST
Atara Biotherapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference Jan 06, 2021 8:30am EST
Atara Biotherapeutics Provides Regulatory Update for Tab-Cel® for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease Jan 04, 2021 7:30am EST
Atara Biotherapeutics Presents First Preclinical Evaluation of ATA3219, a Next-Generation Allogeneic CD19 CAR T Cell Therapy, at the 62nd American Society of Hematology (ASH) Annual Meeting Dec 07, 2020 7:00am EST
